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Introduction: Although vertebral and epidural metastases are common, intradural metastases and intramedullary
spinal cord metastases are rare. The indications for the treatment of intramedullary spinal cord metastases remain
controversial. We present the first biopsy-proven case of an intramedullary spinal cord metastasis from
adenocarcinoma of the prostate.
Case presentation: Our patient was a 68-year-old right-handed Caucasian man with a Gleason grade 4 + 3 prostate
adenocarcinoma who had previously undergone a prostatectomy, androgen blockade and transurethral debulking.
He presented with new-onset saddle anesthesia and fecal incontinence. Magnetic resonance imaging
demonstrated a spindle-shaped intramedullary lesion of the conus medullaris. Our patient underwent
decompression and an excisional biopsy; the lesion’s pathology was consistent with metastatic adenocarcinoma of
the prostate. Postoperatively, our patient received CyberKnifeW radiosurgery to the resection cavity at a marginal
dose of 27Gy to the 85% isodose line. At three months follow-up, our patient remains neurologically stable with no
new deficits or lesions.
Conclusions: We review the literature and discuss the indications for surgery and radiosurgery for intramedullary
spinal cord metastases. We also report the novel use of stereotactic radiosurgery to sterilize the resection cavity
following an excisional biopsy of the metastasis.Introduction
Adenocarcinoma of the prostate affects up to 70% of
men over 80 and is the second leading cause of cancer-
related death in men [1]. Skull and spinal metastases
occur in up to 10% of patients with prostate cancer but
intradural lesions are uncommon. We are aware of no
prior reports of biopsy-proven intramedullary spinal
cord metastases (ISCMs) due to prostate cancer. Con-
ventional radiation has been the historic treatment of
choice for radiosensitive ISCMs, with surgery preferred
in select cases [2,3]. Stereotactic radiosurgery (SRS) has
been discussed as a primary treatment for ISCMs [4,5].
Furthermore, SRS is a favored alternative to postopera-
tive whole brain radiotherapy (WBRT) following the* Correspondence: sdchang@stanford.edu
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reproduction in any medium, provided the orresection of a brain metastasis [6]. We report the first
biopsy-proven case of an ISCM from prostate cancer
and discuss a novel treatment regimen: the use of a
radiosurgical boost to the resection cavity of an ISCM as
an alternative to postoperative spinal radiation for a rela-
tively radioresistant metastasis.Case presentation
A 68-year-old, right-handed Caucasian man was diag-
nosed with Gleason grade 4 + 3 adenocarcinoma of the
prostate in March 2009. A partial prostatectomy and
pelvic node dissection was completed, and our patient
started androgen blockade with leuprolide (Lupron),
dutasteride (Avodart) and bicalutamide (Casodex). His
prostate specific antigen (PSA) levels decreased from an
initial value of 41.6 to 0.07 ng/ml in April 2010. In May
2010, one month prior to admission, a transurethral
debulking of his prostate was completed for difficulty in
initiating a urine stream and an indwelling Foley cath-
eter was left in place. In the 48 hours prior to admission,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Sagittal T2-weighted magnetic resonance image.
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of admission, June 10 2010, he described increasing
headache as well as new-onset fecal incontinence but de-
nied weakness. His past history, family history and a re-
view of his systems were not significant.
On admission, his mental status, cranial nerve and
upper extremity examinations were unremarkable. A
motor examination was intact in his legs but there was
significant numbness below his ninth thoracic vertebra.
Reflexes were absent in his lower extremities. Rectal sen-
sation and tone were absent.
Magnetic resonance imaging scans of his brain and
thoracic and lumbar spine showed two irregularly en-
hancing lesions. The first, 2cm in diameter, was in the
region of the fourth ventricle but was without secondary
hydrocephalus. The second was a spindle-shaped intra-
medullary lesion of the conus medullaris (Figures 1, 2
and 3). The lesion was approximately 2cm in the vertical
extent and appeared partially cystic.
Our differential diagnosis included ependymoma,
astrocytoma, a metastasis from the known prostate can-
cer or a metastasis from an undiscovered second pri-
mary tumor.
Because of our patient’s increasing neurological deficit,
and given the uncertainty of the diagnosis, a decompres-
sion and an excisional biopsy were undertaken on the
day of admission. With somatosensory and motor
evoked potential monitoring, a twelfth thoracic to first
lumbar vertebral laminectomy was completed. The level
of the lesion was confirmed using intraoperative ultra-
sound. On opening the dura, abnormal appearing tissueFigure 1 Sagittal contrast-enhanced T1-weighted magnetic
resonance image.was immediately identified involving the posterior sur-
face of the conus. A small biopsy was consistent with
malignant tissue. A more aggressive resection to the
edges of the abnormal appearing tissue was completed
and his cord appeared adequately decompressed. The
closure was uneventful.
On microscopy, the lesion showed sheets and nests of
cells with abundant cytoplasm and prominent nucleoli.
Mitoses were common. Intracytoplasmic and extracellu-
lar mucin was demonstrated. AEI/AE3 cytokeratin,
CAM5.2, CK7, and CK20 were positive. PSA, ProstaticFigure 3 Axial contrast-enhanced T1-weighted magnetic
resonance image.
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factor-1 (TTF-1), caudal type homeobox-1 (CDX-1), and
S100 were negative. The pathology was consistent with
metastatic adenocarcinoma of the prostate (Figure 4).
Following surgery, his sensory changes improved and
the motor examination remained intact. His bowel and
bladder function remained poor. The intracranial lesion
and the resection cavity in the conus were both treated
with CyberKnifeW radiosurgery. The spinal resection
cavity, contoured to the edge of the enhancing tumor on
a postoperative scan, was treated to a marginal dose of
27Gy at the 85% isodose line in three sessions. Our pa-
tient remains neurologically stable three months after
treatment, with no new neurological deficits and no new
lesions.Discussion
Although vertebral and other epidural metastases are
common, intradural metastases are rare. ISCMs repre-
sent only 0.9% to 2.1% of autopsy cases in patients with
cancer and only 5% of these are identified antemortum
[2]. Adenocarcinoma of the prostate affects up to 70% of
men over 80 and is the second leading cause of cancer-
related death in men [1]. Meningeal carcinomatosis,
brain metastases and intradural extramedullary spinal
lesions are uncommon. One prior case report discussed
a possible prostate ISCM [7]. To date, however, there
have been no reports of biopsy-proven prostate cancer
metastatic to the spinal cord.
The diagnosis of ISCMs is usually radiographic. Mye-
lography may show a fusiform enlargement of the cord
but is non-diagnostic in 40% of cases. Although cerebral
spinal fluid (CSF) is frequently abnormal, malignant cells
are present in only the minority of cases. Interestingly,
Schaller et al. demonstrated in a case report that PSA in
the CSF may be a useful diagnostic tool for detectingFigure 4 Hematoxylin and eosin stained section.intradural prostate metastasis [8]. There are currently no
published treatment guidelines for this ISCM, but
options include conventional radiation, SRS, surgery,
steroids and chemotherapy.
Conventional radiation has been the historic treatment
of choice [2,3,9]. It is effective for radiosensitive ISCMs
but not radioresistant tumors, such as prostate tumors.
Surgery is considered for the palliation of pain or the
prevention of paraplegia when the medical condition of
the patient is appropriate [3,10]. Steroids are appropriate
as an adjunct. Chemotherapy has been used in combin-
ation with surgery or radiation for sensitive tumors, such
as small-cell carcinomas, while SRS is increasingly a
consideration for ISCMs.
Several authors have described SRS as a primary treat-
ment for ISCMs. Parikh and Heron [4] described a sin-
gle patient with a renal cell metastasis treated with
CyberKnifeW, at a 15Gy marginal dose in three fractions.
Their patient had no recurrence in the 26 months of fol-
low-up. Shin et al. [5] presented nine patients, of whom
six had ISCMs. As in the patient of Parikh and Heron,
all of Shin’s patients also had brain metastases. Various
linear accelerator systems were used. A median marginal
dose of 14Gy was delivered in one fraction. The neuro-
logical examinations of five of the six patients improved
and one remained unchanged. In five of six patients with
an ISCM, local control was achieved. Of note, in both
studies the cord dose exceeded the 10Gy maximum dose
that is considered safe. In neither case reports were radi-
ation-related complications reported.
An SRS boost to the resection cavity is an appropriate
postoperative alternative to WBRT in patients with
brain metastases. Kim et al. [11] described the use of
re-resection coupled with Gamma Knife SRS in 79
patients whose brain metastases recurred after both
resection and postoperative WBRT. Their local control
rate, in this group who had failed surgery and WBRT,
was 94.9% and the mean survival time was 17 months.
Complications included radionecrosis in 5% to 10% of
cases. Soltys et al. [12] presented 72 patients treated
with CyberKnifeW SRS after resection instead of WBRT.
Local control was 86% in those treated to the margin of
the enhancing tumor, but was 100% in those where the
treatment volume extended 2mm beyond the edge of
the contrast-enhancing resection cavity. A subsequent
course of WBRT was required for other lesions in 19%
of patients (in a mean of six months after SRS). Mean
overall survival was 15 months but excluding non-
neurological causes of death was 16.9 months. Hwang et
al. [6] directly compared postoperative Gamma Knife
SRS and WBRT in 43 patients (25 SRS and 18 WBRT).
Local control was 100% for SRS-treated patients and
83% in the WBRT group. Median survival was 15
months for SRS-treated patients and 6.8 months for the
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tant recurrences were added to the model. SRS to the re-
section bed of brain metastases was therefore similar or
superior in efficacy to postoperative WBRT, the neuro-
logical risks associated with WBRT were avoided and
the long time required for treatment was decreased from
weeks to five or fewer days.
At present, there is no study in the literature that dir-
ectly compares success rates for radiotherapy alone, sur-
gery alone or surgery plus radiotherapy for ISCMs. We
feel it is likely that the efficacy of the various treatments
of ISCMs would parallel that of brain metastases, and
that a local boost to a resection cavity in the spinal cord
should be as effective as conventional postoperative
spinal radiation while potentially decreasing risk and
minimizing the length of treatment. It also seems rea-
sonable to use SRS for lesions, such as prostate lesions,
that respond poorly to conventional radiation and are
shown to respond well to SRS in the brain [10].
This patient had good residual lower extremity func-
tion and a lesion whose pathology was uncertain. Sur-
gery was recommended to preserve function, was
completed without incident and was followed by clinical
improvement. After surgery, conventional radiation and
SRS treatment were considered. An SRS boost to the re-
section cavity was recommended once the pathology
confirmed the metastasis as from the prostate.Conclusions
Metastases to the intramedullary spinal cord are rare
and typically occur late in the course of the disease. Sur-
gery is appropriate for those patients who can tolerate
the operation and who are in danger of permanent loss
of function or who have intractable pain. After surgery,
conventional spinal radiation has been provided to de-
crease the risk of local recurrence. There is risk to spinal
radiation and not all tumors are radiosensitive. We
propose that a local cavitary boost with SRS may be as
effective as conventional radiation for some tumors
while offering greater convenience and perhaps less risk.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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